Improving survival in people with severe psychiatric disorders

A recently published editorial suggests a potential turning point in the treatment of serious mental illnesses. Researchers propose that medications already widely used for type 2 diabetes and obesity – glucagon-like peptide 1 (GLP-1) receptor agonists – could help reduce the significant mortality gap experienced by individuals with conditions like schizophrenia and bipolar disorder. This potential benefit stems from addressing underlying cardiovascular and metabolic risks.

The Rise of GLP-1 Receptor Agonists

The first GLP-1 receptor agonist, exenatide, received approval from the United States Food and Drug Administration in 2005 for treating type 2 diabetes. Since then, several GLP-1 agonists have been approved, including tirzepatide, which targets both GLP-1 and glucose insulinotropic polypeptide (GIP) receptors. Further development is underway for dual and triple agonists targeting GIP, GLP-1, and glucagon receptors.

These medications have expanded beyond diabetes and weight management. Approvals now include treatment for metabolic dysfunction-associated steatohepatitis, obstructive sleep apnea, reduction of cardiovascular events in those with diabetes and cardiovascular disease, and slowing the progression of chronic kidney disease. Oral formulations of GLP-1 agonists are anticipated in 2026, potentially improving access and ease of use.

The Cardiometabolic Burden on Mental Health

Serious mental illnesses – including schizophrenia, major depressive disorder, and bipolar disorder – significantly impact healthspan and contribute to premature mortality. Individuals with these conditions often experience a reduction in years of life, estimated between 5 and 25 years, largely due to increased rates of cardiovascular disease. Affordable and effective interventions are needed to address this disparity.

Did You Know? Individuals with serious mental illnesses may experience a loss of 5 to 25 years of life compared to the general population.

Current Treatments and Their Limitations

While antipsychotics, lithium, antidepressants, and anticonvulsants are effective psychiatric treatments, reductions in healthspan loss and cardiovascular mortality have been limited. Certain agents, like second-generation long-acting antipsychotics, lithium, and clozapine, have shown some benefit. However, lithium remains under-prescribed despite its efficacy in bipolar disorder.

Emerging Applications of GLP-1 Receptor Agonists

GLP-1 receptor agonists are already recommended for managing weight gain associated with psychotropic medications. There is also preliminary evidence suggesting a potential protective effect against lithium-induced nephrotoxicity, a condition currently lacking approved therapies. Research is also exploring their potential in treating alcohol, tobacco, and opioid use disorders.

Expert Insight: The editorial highlights that the potential of GLP-1 receptor agonists lies in addressing the underlying physical health issues – cardiometabolic factors – that contribute to the increased mortality rates seen in individuals with serious mental illnesses, rather than serving as a replacement for established psychiatric care.

Studies suggest potential benefits in preventing and treating mood disorders, as well as improving cognitive function and addressing anhedonia – a diminished ability to experience pleasure.

Safety Considerations

Several safety factors are important to consider when using GLP-1 receptor agonists in individuals with serious mental illnesses. The constipating effects of these medications may interact with gastrointestinal issues caused by psychotropic drugs. Increased risks of pancreatitis and sarcopenia, conditions more common in this population, also require consideration. Additionally, certain GLP-1 agonists are contraindicated in severe renal disease, which is more prevalent among individuals with serious mental illnesses. While early reports raised concerns about suicidality, larger studies have not established a causal link, though ongoing monitoring is advised.

Looking Ahead

Individuals with serious mental illnesses experience a disproportionate share of years of life lost. Despite advancements in psychopharmacology, the mortality gap persists. GLP-1 receptor agonists represent a promising pharmacological class, but addressing challenges related to cost, access, reimbursement, and supply is crucial. Prioritizing this population within fair allocation frameworks could help reduce premature mortality.

Frequently Asked Questions

What are GLP-1 receptor agonists?

GLP-1 receptor agonists are medications originally developed for type 2 diabetes that have shown promise in treating obesity and related metabolic conditions. They work by mimicking the effects of a natural hormone that regulates blood sugar and appetite.

Why are these drugs being considered for people with serious mental illnesses?

Individuals with serious mental illnesses often experience higher rates of cardiovascular and metabolic diseases, contributing to a shorter lifespan. GLP-1 receptor agonists may help address these underlying health issues, potentially improving overall health and longevity.

Are there any safety concerns with using these drugs in this population?

Yes, potential safety concerns include interactions with other medications, increased risk of pancreatitis and sarcopenia, and contraindications for individuals with severe renal disease. Ongoing monitoring is advisable.

As research continues, will these medications truly bridge the gap in health outcomes for those living with serious mental illness?